| Revenue growth | Q4 revenue grew 10% YoY to INR 64 crores. |
|---|---|
| Margins | EBITDA margins stable at 16% for Q4; FY26 margin approx 21%. |
| Demand visibility | Strong demand in Gynaecology and Dermatology therapies. |
| Management confidence | High confidence in 1.5x IPM growth and accelerating FY27 momentum. |
Growth
FY26 Net Profit grew 19% before exceptions. Q4 PAT rose 31% YoY to ₹9cr with 14% margin.
Outlook
Targeting 1.5x Indian Pharma Market growth (approx. 12-15%); ₹40cr buyback and 200% dividend announced.
Risks
Macro risks and execution on new molecules; potential cost pressures from raw materials and packaging via CMOs.
Earnings Call filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹242.29
- Market cap
- ₹1,598 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 35.1×Sector 50.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Earnings Call Transcript: Key Takeaways
Jagsonpal reported a strong Q1FY27 with 9% revenue growth and 22% PAT growth, outperforming industry rates. The focus is on higher-margin specialty segments and integrating the Equitas acquisition to enter the hospital channel.
- Call
- Guides 18% growth
Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Jagsonpal Pharmaceuticals reported a strong start to FY27 with revenue up 9% YoY and PAT up 22%. The company completed the Aequitas acquisition to enter the hospital supplies segment.
Jagsonpal Pharmaceuticals Q1 FY27 Results: Net Profit ₹13.2 Cr, Up 22.2% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹82.2 Cr (+8.7% YoY) and net profit of ₹13.2 Cr (+22.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹13.2 Cr · +22.2% YoY
Jagsonpal Pharmaceuticals Earnings Call: Key Takeaways
Jagsonpal Pharmaceuticals reported strong FY26 results with 7% revenue growth and 19% PAT growth. Strategy focuses on an asset-light model, high-margin Rx brands, and shareholder returns via buybacks and dividends.